Summary of Conference Call for Yuan Dong Bio (苑东生物) Company Overview - **Company**: Yuan Dong Bio (苑东生物) - **Industry**: Pharmaceutical, focusing on drug development and research Key Points R&D Performance and Future Outlook - Yuan Dong invests 20% of its revenue annually in R&D, ranking among the top in the A-share market [3] - The company is transitioning from high-end generic drugs to more competitive controlled narcotics, achieving significant results [3] - Two Class II controlled narcotics, Nabuphine and Butorphanol, are expected to be approved in 2024, with sales projected to grow from 60 million RMB in 2025 to over 200 million RMB by 2026 [3][4] - The company faces challenges in the non-controlled antagonist product segment due to centralized procurement impacts, and its efficiency in developing new Class I drugs is lagging behind competitors [3][5] Strategic Developments - The Shanghai Chaoyang platform enhances the company's capabilities in developing Class I new drugs, particularly the IKZF13 molecular glue for multiple myeloma, which has a significant market potential [6][7] - HP001, a new drug in clinical trials, shows promising results with an objective response rate (ORR) of 83.3% in high-dose groups, outperforming some combination therapies [10] Competitive Landscape - The company is monitoring competition from BeiGene and Nurix in the BTK ProTech product space, with HP002 aiming to replicate BeiGene's success [11] - VAVONE molecular glue HP003 is being developed to target autoimmune oral therapies, showing better efficacy than existing products [12] Future R&D Directions - The company plans to extend its R&D focus to the Dac platform, utilizing molecular glue as a payload, with promising preliminary data [13] - Key developments expected by 2026 include significant data from VIV1 molecular glue, BDK protect IND, and IKZF13 molecules [13] Financial Projections - The overall valuation of the company is projected to reach 25.5 billion RMB by 2026, with the main business valued at approximately 8 billion RMB [14] - Anticipated profits for 2025 are estimated between 270 million to 280 million RMB, with a growth rate of over 20% expected to continue [14][15] Additional Insights - The company has faced challenges in the past few years, particularly in the Class I new drug sector, with only one drug entering Phase I clinical trials in the last decade [5] - The focus on improving R&D efficiency and quality is expected to positively influence future operational trends [15]

Core Viewpoint - Yuan Dong Bio announced a capital increase of 85.71 million yuan in Shanghai Chaoyang Pharmaceutical, raising its stake from 30.68% to 51.48%, making it a controlling subsidiary [1][5] Group 1: Investment Details - The capital increase price is set at 2.27 yuan per registered capital [1] - The valuation of Shanghai Chaoyang doubled within a month, despite no significant changes in its fundamental projects or clinical progress [1][6] - The total market value of Shanghai Chaoyang's equity was assessed at 198.68 million yuan, with an increase of 175.65 million yuan, representing a growth rate of 762.81% [3] Group 2: Company Background - Shanghai Chaoyang, established in 2021, focuses on new drug development for oncology and autoimmune indications, and has not yet achieved profitability [2] - The company reported zero revenue for 2024 and the first eight months of this year, with net losses of 27.06 million yuan and 3.64 million yuan, respectively [2] Group 3: Drug Pipeline - Shanghai Chaoyang's lead drug, HP001, is in Phase I clinical trials and shows "Best-in-Class" potential for treating multiple myeloma and non-Hodgkin lymphoma [3] - Another drug, HP002, is in the preclinical stage and is expected to enter Phase I clinical trials in Q4 of this year [3] Group 4: Shareholder Structure - The actual controller of Shanghai Chaoyang is Wang Ying's son, who is also the chairman of Yuan Dong Bio [4] - Beijing Qili Jia Technology, a former significant shareholder, has exited its position in Shanghai Chaoyang [5]